Dupixent submits its third listing application in China, JAK inhibitor wants to carve up its AD market

In addition to JAK inhibitors, in the AD field, Dupixent is also facing competition from other types of drugs, such as Maruho's IL-31RA targeting monoclonal antibody nemolizumab, LEO Pharma's IL-13 targeting monoclonal antibody tralokinumab, and Novartis IL-17C targeting monoclonal antibody.
Anti-MOR106, Kyowa Kirin OX40 targeting monoclonal antibody KHK4083
.

► Nemolizumab is a humanized monoclonal antibody developed by Chugai Pharmaceutical, which targets to block IL-31 receptor A.
In September 2016, Maruho obtained the development and commercialization rights for the treatment of skin diseases in the Japanese market
.

► tralokinumab is a fully human IgG4 monoclonal antibody that acts by neutralizing interleukin 13 (IL-13) potently and specifically
.
The drug was authorized by LEO Pharma from AstraZeneca.
In July 2020, the US FDA accepted its application for a biological product license for the treatment of adult AD
.

► MOR106 is a monoclonal antibody drug that targets interleukin 17C (IL-17C)
.
In September 2018, Novartis, Galapagos NV and MorphoSys AG reached an exclusive license agreement of up to US$1.
11 billion for the experimental anti-inflammatory drug MOR106
.
Obtained the exclusive global development and commercialization rights of MOR106 for the treatment of AD and all other potential indications
.

► KHK4083 is a potential first-in-class fully human monoclonal antibody against OX40.
It was discovered by Kyowa Kirin and produced by the company’s patented POTELLIGENT® defucosylation technology to enhance Its antibody-dependent cellular cytotoxicity (ADCC) activity
.
In February of this year, the Phase 2 study of KHK4083 in the treatment of adult patients with moderate to severe AD reached its primary endpoint
.